ArriVent BioPharma (AVBP) catalysts

Upcoming FDA decisions and readouts we track for ArriVent BioPharma, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for ArriVent BioPharma (AVBP, listed on Nasdaq). It concerns Firmonertinib (First-line EGFR exon 20 insertion NSCLC).

First on the list: the Phase 3 readout for Firmonertinib (First-line EGFR exon 20 insertion NSCLC), guided by the company to H2 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker: AVBP
Next catalyst: H2 2026
Type: Phase 3 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
ArriVent BioPharma AVBP · Nasdaq	Firmonertinib	First-line EGFR exon 20 insertion NSCLC	H2 2026 company guidance	Phase 3 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states "Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study ... is anticipated in 2H 2026." Source: 8-K exhibit 99.1, filed 12 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Cullinan Therapeutics (CGEM)EGFR exon 20 insertion NSCLC, second line
Whitehawk Therapeutics (WHWK)EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer; Advanced ovarian and endometrial cancers
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
Dyne Therapeutics (DYN)Duchenne muscular dystrophy, exon 51 skipping
Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor
Xilio Therapeutics (XLO)Metastatic NSCLC (masked PD-1/IL-2 bispecific)